Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EARLY Pregnancy GLucose prOfiles in Women With and Without GDM Risk Factors: EARLY-GLOW (EARLY-GLOW)

24 augusti 2026 uppdaterad av: DCB Research AG

Background:

Gestational diabetes mellitus (GDM) is associated with increased maternal and neonatal complications, including macrosomia, preeclampsia, and long-term metabolic consequences for both mother and child. Current screening methods, primarily the oral glucose tolerance test (OGTT), are typically performed between 24 and 28 weeks of gestation and may miss earlier metabolic alterations. Continuous glucose monitoring (CGM) offers a detailed assessment of glucose dynamics and could potentially identify subtle dysglycemia before GDM becomes clinically apparent.

Objective:

The EARLY-GLOW study aims to characterize glucose patterns during early pregnancy and identify CGM-derived thresholds for early dysglycemia in women with and without established risk factors for GDM. The study seeks to determine whether specific combinations of glucose level and duration of hyperglycemic exposure can distinguish women at increased risk of GDM before routine diagnosis. Additionally, it will explore the relationship between glucose profiles and modifiable lifestyle factors such as diet, physical activity, sleep, and stress, while evaluating the feasibility, usability, and acceptance of CGM technology during pregnancy.

Study Design:

EARLY-GLOW is a prospective, decentralized, observational pilot study conducted in Switzerland from July 2026 to June 2027. The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation. Participants will be stratified into two equal groups: women with at least one recognized GDM risk factor and women without risk factors.

Methods:

Participants will wear a blinded Dexcom G7 CGM continuously from approximately gestational week 12 until routine OGTT screening between weeks 24 and 28 (up to 16 weeks of monitoring). During the study, participants will periodically record fasting blood glucose measurements, dietary intake, meal photographs, sleep quality, physical activity, stress, and well-being through REDCap questionnaires. In the final two weeks of follow-up, participants may additionally use an unblinded FreeStyle Libre 3 CGM to assess user experience. Pregnancy outcomes will be collected approximately six weeks postpartum.

Endpoints:

The primary endpoint is the identification of CGM-derived thresholds combining glucose concentration and duration of exposure that best discriminate between women with and without GDM risk factors. Secondary outcomes include the frequency and duration of hyperglycemic events, time above and below glucose target range, glycemic variability, postprandial glucose excursions, nocturnal glucose patterns, correlations with lifestyle factors, and device adherence and usability.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

The EARLY-GLOW study is a prospective, decentralized observational pilot study that aims to improve understanding of glucose regulation during early pregnancy and identify early signs of gestational diabetes mellitus (GDM) before conventional diagnosis. While current GDM screening relies primarily on an oral glucose tolerance test (OGTT) performed between 24 and 28 weeks of gestation, growing evidence suggests that disturbances in glucose metabolism may already be detectable much earlier in pregnancy. Continuous glucose monitoring (CGM) offers the opportunity to capture detailed glucose patterns throughout the day and may reveal subtle abnormalities that are not identified through standard screening methods.

The study will recruit 48 pregnant women with singleton pregnancies at approximately 12 weeks of gestation from across Switzerland. Participants will be stratified into two groups: women with at least one established risk factor for GDM and women without known risk factors. Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk.

After enrolment, participants will wear a blinded Dexcom G7 continuous glucose monitor for approximately 12 to 16 weeks, covering the period from early pregnancy until routine GDM screening. Because the sensor is blinded, participants will not be able to see their glucose values during the main observation period, minimizing the risk that knowledge of glucose levels influences behavior. At regular intervals, participants will also record fasting blood glucose measurements, upload meal photos, document nutritional intake, and complete questionnaires regarding sleep, stress, well-being, physical activity, and pregnancy-related symptoms. During the final two weeks of follow-up, participants may additionally wear an unblinded FreeStyle Libre 3 sensor to evaluate user experience and compare acceptance of the two most commonly used CGM systems in Switzerland.

The primary objective of the study is to identify CGM-derived thresholds that characterize early dysglycemia in pregnancy. Rather than focusing solely on a glucose value, the study aims to determine combinations of glucose level and duration of exposure that best distinguish women with and without GDM risk factors. This approach acknowledges that the clinical significance of elevated glucose levels may depend not only on how high glucose rises, but also on how long those elevations persist.

Secondary objectives include comparing the frequency and duration of hyperglycemic episodes between risk groups, assessing time spent above and below target glucose ranges, evaluating measures of glycemic variability, and characterizing postprandial and nocturnal glucose patterns. The study will also investigate the relationship between glucose profiles and lifestyle factors such as diet, sleep quality, physical activity, stress, and well-being. Furthermore, participant adherence, device wear time, comfort, usability, and acceptance of the CGM systems will be assessed to determine the feasibility of large-scale CGM use during pregnancy.

To analyze the data, researchers will use both traditional statistical methods and exploratory pattern-recognition techniques. Receiver operating characteristic (ROC) analyses will be applied to identify glucose thresholds and durations that best discriminate between women at higher and lower risk of GDM. In addition, clustering and glucose-profile analyses will be used to describe different glycemic phenotypes during pregnancy and to identify potentially clinically relevant patterns.

The study is observational, no therapeutic interventions are performed. Participants may benefit indirectly from the nutritional consultation offered at the end of the study, during which glucose data and dietary habits are reviewed with a nutrition specialist. More importantly, the knowledge generated by the study may contribute to improved screening strategies, earlier identification of women at risk for GDM, and the future development of personalized preventive interventions.

Studietyp

Observationell

Inskrivning (Beräknad)

48

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study plans to recruit 48 pregnant women who are approximately in the 12th week of gestation (GW).

Potential study participants will be stratified into two mutually exclusive groups: individuals without risk factor according to the Swiss Expertenbrief No. 8118 or at least one with the exception of age >35 years, which will not be considered for the stratification allocation. The following risks will be considered:

  • History of bariatric surgery
  • Pre-pregnancy BMI >30 kg/m²
  • Non-European background (Africa, Asia, Latin America)
  • First-degree relative with type 2 diabetes
  • Previous gestational diabetes
  • Previous macrosomic (>4000 g) offspring
  • Diagnosis of polycystic ovary syndrome (PCOS) or polyendocrine metabolic ovarian syndrome (PMOS)
  • Early pregnancy symptoms suggestive of diabetes (e.g. frequent urination, excessive thirst, glucosuria)

Beskrivning

Inclusion Criteria:

  • Female sex
  • Aged ≥18 years at inclusion
  • Pregnant with singleton ≤12 GW
  • Willingness to wear a CGM device for 12-16 weeks
  • Signed informed consent

Exclusion Criteria:

  • Pre-existing type 1 or type 2 diabetes mellitus or known prediabetes
  • Diagnosis of GDM during current pregnancy
  • Known allergy to adhesive materials or sensor components
  • Inability to follow procedures or insufficient knowledge of project languages (German, French or English)
  • Inability to give consent.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Pregnant women with at least one risk factor for GDM
Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk.
Pregnant women with no risk factors for GDM
Risk factors include obesity, previous gestational diabetes, a family history of type 2 diabetes, polycystic ovary syndrome, previous macrosomic offspring, bariatric surgery, and certain ethnic backgrounds associated with increased GDM risk.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
CGM-derived threshold(s) for early dysglycemia during pregnancy
Tidsram: From 12 weeks of gestation until routine OGTT screening (24-28 weeks of gestation; up to 16 weeks of CGM monitoring)
Identification of one or more continuous glucose monitoring (CGM)-derived thresholds combining glucose concentration and duration of hyperglycemic exposure that best discriminate between pregnant women with and without risk factors for gestational diabetes mellitus (GDM). Thresholds will be identified using receiver operating characteristic (ROC) analyses based on CGM data collected during early pregnancy.
From 12 weeks of gestation until routine OGTT screening (24-28 weeks of gestation; up to 16 weeks of CGM monitoring)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of hyperglycemic events per day
Tidsram: From 12 to 28 weeks of gestation (during CGM wear period)
Mean number of hyperglycemic events per participant per day, defined as sensor glucose values >7.8 mmol/L for at least 10 consecutive minutes.
From 12 to 28 weeks of gestation (during CGM wear period)
Time spent above 7.8 mmol/L
Tidsram: From 12 to 28 weeks of gestation
Average duration per day (minutes/day) with sensor glucose values >7.8 mmol/L.
From 12 to 28 weeks of gestation
Time above 7.8 mmol/L and time to >7.8 mmol/L after logged-in meals
Tidsram: From 12 to 28 weeks of gestation
Time after logged-in meal that individual spends >7.8 mmol/L and timing when first value postprandial >7.8 mmol/L
From 12 to 28 weeks of gestation
Time to Return to Preprandial Glucose Following Meals
Tidsram: From 12 to 28 weeks of gestation
Time required for postprandial glucose levels measured by continuous glucose monitoring (CGM) to return to the pre-meal glucose value after participant-logged meals.
From 12 to 28 weeks of gestation
Mean 24-hour glucose concentration
Tidsram: From 12 to 28 weeks of gestation
Average sensor glucose concentration (mmol/L) over a 24-hour period during the monitoring phase.
From 12 to 28 weeks of gestation
Time above range (TAR)
Tidsram: From 12 to 28 weeks of gestation
Percentage of time with sensor glucose values >7.8 mmol/L as measured by CGM.
From 12 to 28 weeks of gestation
Time below range (TBR)
Tidsram: From 12 to 28 weeks of gestation
Percentage of time with sensor glucose values <3.5 mmol/L as measured by CGM.
From 12 to 28 weeks of gestation
Glycemic variability
Tidsram: From 12 to 28 weeks of gestation
Glycemic variability assessed using standard deviation (SD) and coefficient of variation (CV) of CGM glucose values.
From 12 to 28 weeks of gestation
Nocturnal glucose profile
Tidsram: From 12 to 28 weeks of gestation
Mean nocturnal glucose concentration (mmol/L) during predefined nighttime hours.
From 12 to 28 weeks of gestation
Nocturnal hypoglycemia
Tidsram: From 12 to 28 weeks of gestation
Percentage of nighttime spent with sensor glucose values <3.5 mmol/L.
From 12 to 28 weeks of gestation
Association between CGM metrics and lifestyle factors
Tidsram: From 12 to 28 weeks of gestation
Correlation between CGM-derived glycemic metrics and participant-reported measures of dietary intake, sleep quality, physical activity, and stress.
From 12 to 28 weeks of gestation
CGM adherence
Tidsram: From 12 to 28 weeks of gestation
Adherence to CGM use measured by percentage of planned monitoring time with valid sensor data and discontinuation rates.
From 12 to 28 weeks of gestation
Device-related adverse events
Tidsram: From first sensor application until end of follow-up (up to 16 weeks)
Number and nature of device-related adverse events, including skin reactions and technical issues associated with CGM use.
From first sensor application until end of follow-up (up to 16 weeks)
CGM device usability and acceptance
Tidsram: End of follow-up (26-28 weeks of gestation)
Participant-reported usability and acceptability of Dexcom G7 and FreeStyle Libre 3, including ease of use, comfort, wearability, and overall user experience. The quesions are assessed on a scale from one to five with five being the most positive score.
End of follow-up (26-28 weeks of gestation)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studiestol: Jardena Puder, Prof, Centre Hospitalier Universitaire Vaudois (CHUV)

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 augusti 2026

Primärt slutförande (Beräknad)

30 april 2027

Avslutad studie (Beräknad)

30 april 2027

Studieregistreringsdatum

Först inskickad

20 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

20 augusti 2026

Första postat (Faktisk)

24 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

26 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera